Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Granules India Business Update

Granules India filed a Paragraph IV ANDA certification for Ruxolitinib ER Tablets, claiming potential 180-day U.S. generic exclusivity, subject to FDA review and confirmation.

Source

BSE filing, NSE: GRANULES. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Granules India Ltd: key numbers

Share price
₹840.45
Market cap
₹20,826 Cr
Revenue (annual)
₹5,366 Cr
Net profit (annual)
₹595.0 Cr
P/E (TTM)
31.4×Sector 46.1×
Promoter holding
37.39%-0.63% QoQ
FII holding
20.25%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Granules India Ltd

All →
11:42 IST BSE
Convertible Warrants

Granules India Convertible Warrants

Promoter group members Uma Devi, Priyanka, Pragnya and Harsha were allotted 2,49,82,906 Granules India shares on warrant conversion. The balance payment totals about ₹1,096.13 crore.

Value
₹1,096 Cr

Other business update announcements

All →